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ABSTRACT 
Monoclonal antibody (mAb)-based therapeutics have established themselves as meaningful 
components of the treatment paradigm for a variety of tumors. However, since the approval of 
rituximab in 1997 as the first mAb-based therapy for cancer, there has been a paucity of novel, 
validated cancer targets for therapeutic intervention by mAbs. In effect, numerous challenges lie in 
the discovery of suitable extracellular or transmembrane antigens that permit the differentiation of 
tumor from healthy tissue. The adaptive immune system, though, mediates recognition of foreign 
antigens derived from the intracellular proteome by T cell receptor (TCR) binding to peptide-loaded 
major histocompatibility complex (pMHC) molecules. Because cancer is associated with large-scale 
alterations in the genome, there are a vast number of novel epitopes presented to the adaptive 
immune system. Although natural TCRs have exquisite functionality in distinguishing these foreign 
epitopes, and several tumor-reactive TCRs have, in fact, been characterized, the molecules 
themselves are poorly developable as therapeutic candidates. Thus, in order to enable TCR-like 
binding of a broader class of protein agents, this study explores the transfer of TCR binding 
domains to other mAb-based scaffolds, including the fibronectin-derived Fn3 and the IgG-derived 
4D5 scaffolds. By using a combination of rational design and directed evolution to guide binding 
domain transfer, evidence for TCR-like binding was demonstrated for several engineered 
molecules. In addition to conferring binding functionality, the grafted TCR domains had a 
deleterious effect on the biophysical properties of these inherently robust protein scaffolds. Thus, 
this work provides novel insight into the objective of developing mAb-based agents with TCR-like 
binding specificity for pMHC antigens, informing future efforts to target the abundance of 
intracellular tumor epitopes.  
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C h a p t e r  1  
INTRODUCTION 
 
Antibody-based therapeutics are effective for the treatment of various cancers 
Since the advent of hybridoma technology in 1975, the development of novel monoclonal 
antibodies (mAbs) as therapeutics has been actively and fruitfully pursued [2]. Generally, mAbs 
possess two distinct functional units: the constant fragment (Fc) and the fragment of antigen 
binding (Fab). In IgGs, the most frequently used class of mAb for immunotherapy, the Fc region 
mediates immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) 
and complement-dependent cytotoxicity (CDC), and modulates pharmacokinetics by binding to 
neonatal Fc receptor (FcRn). The Fab domain contains the variable region, comprising six 
hypervariable complementarity-determining regions (CDRs) that bind antigen and confer 
specificity. 
Over the past two decades, mAbs have increasingly demonstrated effectiveness in the treatment of 
patients with cancer. Therapeutic mAbs specifically target antigens expressed on the tumor cell 
surface (Her2, EGFR, CD20) or proteins in the tumor microenvironment that promote malignant 
growth and immune evasion (VEGF, CTLA-4). These mAbs act through antagonizing the function 
of a pro-tumorigenic ligand or receptor, modulating the immune system through Fc-mediated 
effector function, or by delivering a specific drug or radioactive isotope to the tumor [3]. 
Furthermore, mAbs may require the concerted action of several of these functions to exert clinical 
efficacy [4]. In addition to IgG therapeutics, several protein drug candidates have emerged that 
make use of non-antibody molecular recognition scaffolds. Similar to mAbs, alternative non-
antibody scaffolds exert a pharmacological effect by binding to a physiological target, and may also 
be coupled to an effector domain, such as an Fc or cytotoxin [5]. For the purposes of this work, 
alternative scaffolds are classified under the general category of mAb-based proteins. 
A key challenge in the development of therapeutic mAbs for oncology has been to identify 
antigens that are suitable targets for therapeutic intervention. In order for an acceptable 
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therapeutic window to exist, a target must be differentially expressed, mutated, or sufficiently 
overexpressed in the tumor relative to healthy tissue; alternatively, the ablation of biological 
function of the target or of cells expressing the target must be tolerated (e.g. CD20, CD19) [6]. 
The challenges in identifying targets that fit these criteria are apparent in the scarcity of targets of 
therapeutic mAbs approved for cancer (Table 1-1). In particular, much of the focus in the 
development of cancer immunotherapies has been to optimize effector function (by modifying Fc 
interactions or conjugating to cytotoxins) or to improve the safety (by eliminating non-human 
sequences) of mAbs against extensively validated targets. Although such efforts have generated 
incremental improvements in the treatment of certain cancers, it will be essential to discover and 
validate novel targets in order to expand the types of tumors that can be treated with mAb-based 
therapies. 
 
The adaptive immune system provides a means of identifying the molecular signatures of tumors 
T cells regulate the process of immune surveillance, in which the adaptive immune system is 
capable of identifying and eliminating somatic cells expressing exogenous proteins. The ability of 
T cells to identify target cells is modulated by the recognition of major histocompatibility 
complex (MHC)-restricted antigens, presented on somatic and professional antigen-presenting 
cells (APCs), by the T cell receptor (TCR), a heterodimeric immunoglobulin superfamily member 
expressed on the surface of T cells. In somatic cells, MHC class I molecules assemble in the 
endoplasmic reticulum (ER) with peptides that are generated from the degradation of intracellular 
proteins by the proteasome [7]. In professional APCs, MHC class II molecules in late endosomal 
compartments associate with peptides generated from the degradation of extracellular proteins by 
lysosomal proteases [8].  
One of the striking features of T cells is their exquisite specificity in distinguishing foreign 
antigens from self-peptides, as well as their sensitivity to a sparse distribution of foreign antigens 
among a large population of presented self-peptides [9]. The diversity of peptide-MHC (pMHC) 
antigens that TCRs are able to recognize is programmed by the clonal variability of their CDRs, 
generated by VJ and V(D)J recombination during T cell development in the thymus. Structurally, 
the CDRs determine recognition of MHC-restricted antigens through loop-mediated contacts; 
CDRs 1 and 2 on both subunits interact primarily with the MHC surface, and the CDR3 of both 
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subunits interact primarily with the exposed antigen epitope (Figure 1-1) [10]. For CD8+ T cells 
recognizing MHC class I-restricted antigens on somatic cells, recognition initiates a signaling 
cascade within the T-cell that ultimately results in the destruction of the infected cell. For CD4+ T 
cells recognizing MHC class II-restricted antigens on professional APCs, recognition initiates the 
release of cytokines that enhances the clearance of pathogens by both humoral and cell-mediated 
mechanisms [11]. 
The theory of cancer immunoediting has emerged over the past several decades to explain the 
role of the adaptive immune system in the pathology of cancer. In particular, tumors may express 
proteins that are differentially upregulated, contain oncogenic mutations, have atypical post-
translational modifications, or are normally expressed only in germline cells (and are thus novel 
to the adult immune system) [12]. Differential presentation by tumors of epitopes from these 
proteins is sometimes sufficient to activate a clonal population of T cells that can recognize these 
tumor-associated antigens (TAAs), resulting in an immune response. The first observation of T 
cell mediated antitumor immunity was in mice that, when pre-immunized with a syngeneic 
tumor, rejected subsequent tumor challenges [13]. In addition, the rejection of transplanted 
tumors was observed in mice that were not pre-immunized, but were transferred lymphocytes 
from pre-immunized mice [14].  
The development of novel in vitro detection and cloning methods that can probe patient-derived T 
cells isolated from the infiltrate of autologous tumors led to the identification of human TCRs 
specific for MHC-restricted tumor antigens, including the Mart1 melanoma differentiation antigen 
and the Ny-Eso-1 cancer-testis antigen [15]. Several TCRs specific for MHC-restricted TAAs have 
since been identified, creating a repertoire of molecules that can target the intracellular tumor 
proteome [16].  
 
Efforts at targeting MHC-restricted TAAs signal promise 
Initial efforts at targeting MHC-restricted TAAs have focused on the utilization of tumor-specific T 
cells. A landmark study by Rosenberg and colleagues in 1988 demonstrated that the adoptive 
transfer of ex vivo-expanded tumor-infiltrating lymphocytes extracted from resected melanomas 
resulted in the specific lysis of autologous tumor cells in humans with metastatic melanoma [17]. 
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The use of adoptive cell therapy (ACT) for the treatment of metastatic melanoma has since been 
extensively validated; objective responses have been observed in up to fifty percent of patients 
refractory to all other treatments options, with several reported complete responses [18]. 
More recent studies have demonstrated that normal human lymphocytes can be genetically 
engineered to recognize cancer antigens and mediate cancer regression in vivo [19]. After the 
successful cloning of the genes encoding TCRs specific for various cancer antigens, normal 
human lymphocytes could be transduced with a retrovirus encoding the TCRs [15]. The TCR-
engineered lymphocytes may then be transferred to patients with metastatic melanoma, 
illustrating that ACT can be applicable to patients who do not possess a sufficient quantity of 
tumor-reactive cells to be expanded ex vivo. 
Despite the promise of ACT, the utility of this method for the treatment of melanoma and other 
tumors has been limited. Indeed, challenges related to the scalability of the ACT process and the 
heterogeneity inherent to cell-based therapies have impeded regulatory and commercial success 
[20]. Furthermore, TCR gene-modified T cells for ACT express both the transduced TCR and the 
endogenous TCR; since TCRs are heterodimers, the concurrent expression of both dimers may 
lead to mispaired TCRs [21]. Such mispairing may then result in reduced functionality of the T 
cells, or unknown specificities that may result in off-target toxicities. An ACT approach that 
bypasses the issue of endogenous TCR chain mispairing is chimeric antigen receptor (CAR) T-
cell therapy, in which the T cell is engineered to express an antibody single-chain Fv (scFv) 
domain fused to the intracellular signaling domains of the CD3-ζ chain and the costimulatory 
molecule 4-1BB [22]. Specifically, the recognition of the B cell antigen CD19 by the expressed 
scFv initiates a signaling cascade that results in the elimination of healthy and malignant B cells. 
Because the entire protein fusion containing the recognition and signaling domain is encoded by a 
single polypeptide chain, there is no concern of mispairing. In order to generalize the CAR 
technique to enable targeting of MHC-restricted antigens, it would be essential to create a single-
chain construct capable of specifically recognizing pMHC. Consequently, attempts engineer 
single-chain analogs of the TCR V-domains have been pursued, with limited success due to the 
inherent instability of V-domain dimers in the absence of constant domains [23]. 
In order to circumvent the concerns intrinsic to cell therapies, there is an incentive to engineer 
pMHC-targeted therapies without the need for cellular components. Bent Jakobsen and 
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colleagues have developed a class of protein reagents, ImmTACs, to bind to pMHC TAAs and 
elicit an effector response by recruiting T cells to the pMHC-expressing tumor [24]. Specifically, 
ImmTACs comprise two domains- a stabilized TCR molecule and an anti-CD3 scFv- fused 
together by a flexible linker. The stabilized TCR domain is engineered for improved affinity and 
stability by introducing a non-native interchain disulfide bond in the constant region, and by 
extensively mutagenizing the CDR and framework regions of the TCR extracellular domain [25]. 
These steps are especially significant as TCRs are generally unstable and not well soluble in their 
native format, and have relatively low affinity for cognate pMHC [26]. Alternatively, the anti-
CD3 scFv serves to localize and activate T cells in a polyclonal manner, similar to the approach 
employed by the bispecific T cell engager (BiTE) mAbs [27]. Notably, the potency of the anti-
CD3 effector function may be critical given the low copy number (as low as 10 to 150 copies per 
cell) of any given pMHC target relative to targets of established mAb therapeutics [28].  
Despite the recent success of ImmTACs, there are several potential drawbacks to the platform. 
For instance, not all TCRs may convert well to ImmTAC format, due to either the incompatibility 
of certain frameworks with the engineered interchain disulfide bond or the lack of expression of 
certain constructs in display format [29]. Furthermore, the introduction of copious non-native 
mutations increases the probability of eliciting and immunogenic response in vivo [30]. The use 
of degenerate codon libraries, while increasing the combinatorial diversity of sequences, may 
increase the likelihood of cross-reactivity to non-target pMHC by creating binders to novel 
epitopes or by biasing the interaction toward the conserved MHC helices [31]. Indeed, a structural 
study of a thus engineered, high affinity variant of the 2C TCR revealed that the gain of affinity 
was the direct consequence of tighter binding to the MHC residues [32]. 
 
Monoclonal antibody-based approaches to pMHC recognition 
In order to avert the concerns related to employing TCR-based scaffolds, several groups have 
focused on the engineering of mAbs against pMHC by exploiting classical techniques. Efforts to 
raise mAbs by immunization and hybridoma technologies have used peptide-pulsed cells [33], 
soluble pMHC [34], and soluble pMHC tetramer [35] as immunogens. The latter approach, 
developed by Weidanz and colleagues has been especially effective in isolating mAbs against 
several different pMHC targets [36]. Concurrently, various groups have used phage display 
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technology in order to isolate pMHC-slective mAbs from immunized murine [37], pre-immune 
[38], or synthetic [39] phage libraries.  
A major drawback associated with using classical antibody engineering techniques to target 
pMHC antigens is the difficulty of achieving peptide specificity. Because the peptide epitope 
comprises a small fraction of the exposed surface of a pMHC, such techniques may yield high 
affinity interactions between the mAb and pMHC antigen that do not necessarily include contacts 
at the MHC-peptide interface. These interactions are undesired because they would lead to cross-
reactivity with MHC displaying irrelevant peptide antigen. Indeed, it is not possible with current 
methods to limit the selection of antibodies to clones that bind the desired peptide epitope; such 
clones must be identified post-selection by further analysis of selected binders, which increases 
the downstream cost and risk of failure.  
Particularly, in cases where interactions between engineered mAbs and pMHC have been 
elucidated, the results are quite provocative. An analysis of determined co-crystal structures 
between TCRs and pMHC reveals that these interfaces possess a large buried surface area of 
interaction with the peptide epitope and a high degree of shape complementarity with exposed 
peptide residues [40]. Furthermore, the structures affirm a conserved binding mode in which the 
TCR is oriented diagonally relative to the long axis of the MHC peptide-binding groove, with the 
Vα domain located over the N-terminal portion of the peptide and the Vβ domain positioned above 
the C-terminal segment of the peptide. Likely, the forces of evolution and the process of selection in 
the thymus drive the TCR-pMHC interactions toward a binding mode that is optimized for 
specificity and sensitivity. In contrast, an X-ray crystal structure of the interaction between the 
engineered Fab Hyb3 and its target, HLA-A1-MAGE-A1, demonstrates considerable deviation 
form a normal TCR-like binding footprint [41]. Specifically, binding is shifted toward the C-
terminal portion of the peptide, suggesting a more promiscuous binding mode in which alternative 
peptides ligands may conceivably be accommodated. Indeed, T cells constructed with Hyb3 fused 
to the TCR signaling domain lacked peptide specificity and killed HLA-A1-positive cells 
irrespective of peptide presentation [42]. 
Thus, it appears critical that the interaction between a pMHC and a protein binder be suitably 
positioned to be optimal for affinity and specificity. Because nature has provided a template, in the 
embodiment of TCRs, for such an optimized binding mode, it would seem desirable to emulate 
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TCR-like binding in the discovery of mAb-based agents targeting pMHC. Although there are 
drawbacks to using TCRs themselves as targeting agents, it would be reasonable to apply the 
concept of binding domain transfer in order to confer the binding elements of TCRs to suitable 
alternative protein scaffolds.  
 
Binding domain transfer enables mimicry of TCR binding mode 
Binding domain transfer is the method of grafting key residues from a binding molecule onto a 
different molecular recognition scaffold. This technique involves the identification of hotspots 
(amino acid residues critical to a specific binding interaction) or a contiguous sequence of residues 
that govern binding (e.g. a CDR loop), followed by the transplantation of the residues to suitable 
positions on the target scaffold, and often accompanied by the diversification of surrounding 
positions on the target scaffold to accommodate the new mutations [43]. Several examples of 
successful transplantation of single loops have been reported, including the grafting of CDR-H3 
from an integrin binding antibody to an exposed loop of tissue-type plasminogen activator [44], 
grafting of CDR3 from a camelid VHH targeting lysozyme to the bacterial chromoprotein 
neocarzinostatin [45], and grafting of CDR-H1 from a CD4 binding antibody to the protein 
inhibitor of neuronal nitric oxide synthase [46]. The transfer of smaller binding elements between 
proteins has also been demonstrated successfully. For instance, the RGD hotspot from fibronectin 
that modulates binding to integrins was grafted onto an exposed loop of the cysteine-knot protein 
AgRP; flanking residues were then randomized with degenerate codons, and functional, integrin-
binding clones were selected using yeast display [47]. In another example, three noncontiguous 
hotspot residues from erythropoietin were grafted onto suitable positions of the unrelated protein 
PLCδ1-PH; computational design was used to generated explicit sequence variants that were 
screened for binding to the erythropoietin receptor in vitro [48]. The simultaneously grafting of 
multiple loops has also been established, a notable example of which is the technique of mAb 
humanization, whereby multiple CDR loops from non-human mAbs are transferred onto 
appropriate human antibody frameworks in order to reduce the immunogenicity of therapeutic 
mAbs [49]. 
The selection of an appropriate target scaffold is a critical step in the process of domain transfer. 
Indeed, several criteria are used to assess the fitness of a target scaffold for the grafted binding 
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elements, including sequence and structural homology [50] and three dimensional orientation 
and positioning of proposed grafting loci [51]. In most cases, the transfer of binding elements 
must be accompanied by diversification of surrounding residues of the target scaffold to recover 
loss of stability or affinity resulting from the chimerism. Techniques used to introduce sequence 
diversity include random mutagenesis and computational design. The latter option has typically 
been employed in cases where the target scaffold is rich in secondary structure, so that the 
conformation of the mutant scaffold may be reliably predicted [52]. In the cases where the 
binding elements comprise loop regions, methods such as site-directed mutagenesis and error-
prone polymerase chain reaction (PCR) are preferred [53]. 
A consequence of using random mutagenesis for the diversification of target scaffolds is the 
requirement of relatively large libraries for generating sufficient diversity to identify functional 
clones. Consequently, ultra high-throughput techniques for screening or selection of positive 
binding, including phage and yeast display, are often necessary. In phage display, a library of 
approximately 1010 protein variants, encoded by a plasmid incorporating a genetic fusion to a 
bacteriophage coat protein, is transformed into a phage-competent bacterial host. The bacteria then 
produce phage mutants displaying library variants that can be panned against immobilized target, 
enabling the isolation of positive binding clones for reinfection and outgrowth of subsequent 
bacterial culture [54]. By contrast, yeast display entails the genetic fusion of scaffold mutants to the 
Aga2p mating adhesion receptor on the surface of S. cerevisiae [55]. Fluorescently labeled target 
protein can then be used to stain yeast, from which cells displaying positive binding clones are 
selected using fluorescence activated cell sorting (FACS). Whereas phage display is often preferred 
for naïve or synthetic libraries because of the capacity for screening a larger number of variants 
(yeast libraries are typically 108 in size), yeast display is often preferred when using affinity 
maturation techniques, such as error-prone PCR, as yeast homologous recombination circumvents 
several cloning steps. Furthermore, eukaryotic hosts lessen the expression biases characteristic of 
bacterially propagated libraries [55]. 
The presence of binding hotspots in the CDR loops of TCRs has been demonstrated using alanine 
scanning mutagenesis, in which alanine substitution mutants are assayed for binding to the usual 
binding partner [56]. In particular, the binding affinity of the alanine mutant relative to that of the 
wild-type protein is used to compute a difference in free energy of binding between the two 
variants, which reveals the relative contribution of a residue’s side chain to a binding interaction. 
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Alanine scanning experiments of TCR-pMHC interfaces reveal that several TCRs contain residues 
that contribute disproportionately to binding of pMHC (Table 1-2). Such studies provide a rationale 
for grafting these key residues, contained in CDR loops, onto a suitable target scaffold in order to 
replicate the archetypal TCR binding mode. As a result, the affinity and specificity of a TCR may 
be transplanted onto a more appropriate framework for developing protein therapeutics. 
 
Fn3 and 4D5 are suitable target scaffolds for TCR binding domain transfer 
The evaluation of target scaffolds for TCR domain transfer should depend on several criteria. 
Chiefly, a suitable scaffold must have ideal characteristics to be developable as a mAb-based 
therapeutic- including high stability, capacity to be engineered (i.e. in a display format), and low 
immunogenicity. Ideally, such a scaffold would also have close structural homology to the TCR 
framework in order to correctly position and orient the grafted hotspots and thus maximize the 
likelihood of successful domain transfer. Because TCRs possess the very prevalent 
immunoglobulin-like fold, characterized by beta-sandwich domains containing flexible loops 
flanked by alternating beta strands, homology exists with several proteins in the immunoglobulin 
superfamily [57].  
Among the structural homologues of TCRs, the most relevant is perhaps the Fab fragment of 
antibodies. In fact, before the first TCR structure was elucidated, sequence analyses correctly 
predicted that TCRs would have a domain topology and binding orientation similar to those of Fabs 
[58]. Among the Fab frameworks, perhaps the most established for therapeutic use is 4D5, a human 
scaffold corresponding to the germ-line sequences IGVH 3–66 and IGVK 1–39 (IMGT 
nomenclature). In addition to constituting the framework of the therapeutic mAb Herceptin, 4D5 
has demonstrated a robust capacity to be engineered, as it is the basis for several reported antibody 
libraries and has been engineered to bind several different antigens by diversification of its CDR 
loops [59-61]. 4D5 furthermore exhibits high heterologous expression yields and above average 
thermodynamic stability [62]. Notably, CDR grafting to 4D5 has previously been used to rescue the 
poor thermodynamic stability and soluble expression yield of a murine anti-fluorescein antibody, 
providing further rationale for transfer of TCR loops [63]. 
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In addition to 4D5, the Fn3 scaffold, based on the human 10th type III fibronectin domain, is also 
a candidate for TCR binding domain transfer. Fn3 is a 10 kDa single-chain beta-sandwich with 
seven beta-strands and three loops clustered on each pole, and has comparable structure and 
geometry to the TCR Vα domain (Figure 1-2). In addition, Fn3 has a high thermodynamic stability, 
and has been used as an alternative non-antibody scaffold (known as “monobody”) to engineer 
binders against several targets in various display formats to affinities as high as 1 pM [64]. Notably, 
an Fn3-based drug candidate targeting vascular endothelial growth factor receptor 2 is currently 
being evaluated in clinical trials for oncology indications, with preliminary evidence of repeated 
dose safety and anti-tumor activity [65].  
Chapter 2 of this thesis examines the binding domain transfer from known tumor-specific TCRs to 
Fn3. In particular, yeast display libraries are constructed by grafting onto the loops of Fn3 the 
corresponding CDR loops from the Vα domain of TCRs specific for human leukocyte antigen 
(HLA) A2 in complex with a peptide derived from the melanoma differentiation antigen Mart1. The 
target HLA-A2-Mart1 is chosen because it is an established MHC-restricted TAA for which several 
well-characterized TCRs are known to bind [66]. Specifically, the determined co-crystal structures 
for the complex between the TCRs and HLA-A2-Mart1 may enable structural modeling and 
examination of selected Fn3 sequences, in order to determine whether key residues governing the 
interaction are conserved following mutagenesis.  
Similarly, Chapter 3 of this thesis investigates the binding domain transfer from known tumor-
specific TCRs to 4D5. Relative to Fn3, 4D5 is a less stable scaffold; namely, the thermodynamic 
stabilities of 4D5 and Fn3 determined by similar methods are 8.1 kcal/mol and 12.6 kcal/mol, 
respectively [67, 68]. Although the lower stability of 4D5 may negatively impact its evolvability in 
general [69], it has significantly closer sequence and structural homology to the TCR framework, 
and may thus be a better candidate for TCR chimeragenesis. Furthermore, the demonstration of 
successful domain transfer onto an additional scaffold would serve to illustrate the efficacy of the 
general technique of TCR binding domain transfer. In addition to investigating the binding domain 
transfer of HLA-A2-Mart1-specific TCRs, Chapter 3 examines the transfer of CDR loops from a 
TCR specific for HLA-A2 in complex with a peptide derived from the cancer-testis antigen Ny-
Eso-1[70]. The corresponding TCR, 1G4, is similarly well characterized with a determined co-
crystal structure [71].  
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To construct diversified libraries of TCR-Fn3 and TCR-4D5 chimeras, a unique application of 
molecular cloning is exploited. In particular, to avoid loss of TCR-like pMHC selectivity, 
diversified positions must be carefully chosen so that potential hotspot residues from parental TCRs 
are preserved. However, because the precise hotspots residues for the Mart1- and Ny-Eso-1-specific 
TCRs are not known, the implementation of traditional site-directed mutagenesis with degenerate 
nucleotides libraries is problematic. Instead, error-prone PCR is preferred as a method of 
diversification, as it can be tuned to introduce combinatorial mutations across long gene segments 
more conservatively than degenerate nucleotides [72]. The specific cloning method, a variation of a 
protocol used to create synthetic Fn3 libraries [73], is adapted to accommodate TCR-to-Fn3 binding 
domain transfer, and is further extended to TCR-to-4D5 binding domain transfer. 
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Target Approved Therapy Indication Notes 
Her2/Neu Herceptin Breast cancer  
Kadcyla Breast cancer DM1-conjugated  
Perjeta Breast cancer  
CD20 Rituxan Lymphoma Murine variable region 
Zevalin Lymphoma Radiolabeled (yttrium-90 or indium-111) 
Bexxar Lymphoma Radiolabeled (iodine-131) 
Gazyva Lymphoma Glyco-engineered Fc 
Arzerra Lymphoma Fully-human mAb 
EGFR Erbitux Colorectal, 
head and neck 
Chimeric IgG1 
Vectibix Colorectal Fully human IgG2 
VEGF Avastin Colorectal  
CTLA-4 Yervoy Melanoma  
CD30 Adcetris Lymphoma MMAE-conjugated 
 
 
 
 
 
 
 
Table 1-1. FDA approved monoclonal antibody-based therapeutics for the treatment of 
cancer. 
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Figure 1-1. X-ray crystal structure of the ternary complex between a T cell receptor 
(rainbow), MHC class I molecule (gray), and an antigenic peptide (magenta). The 
CDR1α (blue) and CDR1β (yellow) interact primarily with MHC helices, while CDR3α 
(green) and CDR3β (red) predominantly contact peptide residues. PDB 2bnr. 
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T cell receptor Antigen PDB Amino Acid Position Chain ΔΔG (kcal/mol) 
TCR LC13 B-8 EBV 1mi5 D 30A Vα 1.64 
TCR LC13 B-8 EBV 1mi5 H 33 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 H 48 Vα 1.12 
TCR LC13 B-8 EBV 1mi5 L 50 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 P 93 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 L 94 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 Y 100 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 K 103 Vα 1.64 
TCR LC13 B-8 EBV 1mi5 S 31 Vβ 1.06 
TCR LC13 B-8 EBV 1mi5 Q 98 Vβ 1.64 
TCR LC13 B-8 EBV 1mi5 Y 100 Vβ 1.64 
TCR LC13 B-8 EBV 1mi5 Q 106 Vβ 1.64 
TCR 2C L(d)-QL9 2oi9 T 29 Vα 2.05 
TCR 2C L(d)-QL9 2oi9 Y 31 Vα 1.33 
TCR 2C L(d)-QL9 2oi9 Y 49 Vα 1.48 
TCR 2C L(d)-QL9 2oi9 Y 50 Vα 1.48 
TCR 2C L(d)-QL9 2oi9 L 104 Vα 1.42 
TCR 2C L(d)-QL9 2oi9 N 31 Vβ 1.48 
TCR 2C L(d)-QL9 2oi9 Y 48 Vβ 1.48 
TCR 2C L(d)-QL9 2oi9 Y 50 Vβ 1.48 
TCR 1934 I-A(u) MBP 2pxy Y 29 Vα 1.2 
TCR 1934 I-A(u) MBP 2pxy R 48 Vα 1.2 
TCR 1934 I-A(u) MBP 2pxy S 50 Vα 1.2 
TCR 1934 I-A(u) MBP 2pxy R 51 Vα 1.2 
TCR 1934 I-A(u) MBP 2pxy N 31 Vβ 1.2 
TCR 1934 I-A(u) MBP 2pxy Y 48 Vβ 1.2 
TCR 1934 I-A(u) MBP 2pxy Y 50 Vβ 1.2 
TCR 1934 I-A(u) MBP 2pxy E 56 Vβ 1.2 
TCR 172 I-A(u) MBP 1u3h L 50 Vα 2 
TCR 172 I-A(u) MBP 1u3h V 52 Vα 2 
TCR 172 I-A(u) MBP 1u3h N 31 Vβ 2 
TCR 172 I-A(u) MBP 1u3h Y 48 Vβ 2 
TCR 172 I-A(u) MBP 1u3h Y 50 Vβ 2 
TCR 172 I-A(u) MBP 1u3h E 56 Vβ 2 
TCR JM22 A-2 Flu 1oga S 32 Vα 1 
TCR JM22 A-2 Flu 1oga Q 34 Vα 1 
TCR JM22 A-2 Flu 1oga D 32 Vβ 1.6 
TCR JM22 A-2 Flu 1oga Q 52 Vβ 2 
TCR JM22 A-2 Flu 1oga I 53 Vβ 2 
TCR JM22 A-2 Flu 1oga N 55 Vβ 1.1 
TCR JM22 A-2 Flu 1oga R 98 Vβ 2 
 
 Table 1-2. Hotspot residues found in TCR-pMHC interfaces, where the definition of hotspot is taken to be a residue that, when mutated to alanine, results in a difference in free 
energy of binding (ΔΔG) of at least 1 kcal/mol. Data is compiled from the Alanine 
Scanning Energetics database (ASEdb) [1]. ΔG of binding is typically determined by SPR. 
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Figure 1-2. Topology diagrams comparing (A) the antibody light chain immunoglobulin 
fold, (B) the T cell receptor alpha chain immunoglobulin fold, and (C) the Fn3 
immunoglobulin fold. Structures of (D) the antibody light chain domain of 4D5, (E) a 
TCR alpha chain domain, and (F) the Fn3, corresponding to PDB ID’s 1n8z, 3qdg, and 
1fna, respectively. Primary binding loops, as well as N- and C-termini are indicated. 
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C h a p t e r  2  
CONSTRUCTION AND SCREENING OF AN FN3-TCR LIBRARY ENABLES THE 
DISCOVERY OF AN HLA-A2-MART1-SELECTIVE CLONE 
Abstract 
The desirability of soluble, single-chain proteins that mimic the peptide-specific binding properties 
of T cell receptors (TCRs) has led to the identification of the human 10th type III fibronectin domain 
(Fn3) as a suitable scaffold for grafting of the TCR binding loops. In order to rationally transfer the 
binding domain of a Mart1-specific TCR to Fn3, a library assembly method was developed with the 
goal of maximal transfer of TCR residues involved in antigen binding and minimal perturbation of 
the Fn3 framework. A novel, mutagenized library assembly method was developed after initial 
screens in yeast display signaled that randomization of the library may be necessary to successfully 
transfer binding properties to the new scaffold. Subsequent screens and selections in yeast display 
led to the identification of an HLA-A2-Mart1 binding clone that was confirmed to be Mart1 
selective. Expression and further characterization of the clone in soluble format demonstrated a 
reduction in yield and solubility relative to wild-type Fn3. However, binding to HLA-A2-Mart1 
antigen was confirmed by surface plasmon resonance (SPR). Although the biophysical properties of 
the isolated clone are suboptimal, the results of the TCR-to-Fn3 binding domain transfer are quite 
instructive of future attempts to engineer molecules with TCR-like binding properties. 
  
  
23 
Introduction 
In Chapter 1, the utility of a single-chain, soluble TCR-like binder to MHC-restricted tumor-
associated antigens is established. Furthermore, a strong rationale is proposed for transferring the 
binding domains from TCRs onto homologous proteins, such as the antibody Fab and the Fn3 
monobody domains. In this study, validation of the approach of TCR-to-Fn3 binding domain 
transfer is ventured by the engineering of a novel binder against HLA-A2-Mart126-35, a target of 
interest in oncology and, specifically, melanoma. Specifically, HLA-A2-Mart1 is targeted by the 
TCRs MEL5 [1], DMF4, and DMF5 [2], which have been well characterized biophysically. 
Fn3 is a single chain, 10 kDa beta-sandwich with seven beta-strands and three loops arranged on 
each pole, and has comparable structure and geometry to the TCR Vα domain (Figure 1-2). In 
addition, Fn3 has a high thermodynamic stability, with a reported melting temperature (Tm) of 88°C, 
and has been used as a scaffold to engineer binders against several targets in various display formats 
with affinities as high as 1 pM [3]. Notably, an Fn3-based drug candidate targeting vascular 
endothelial growth factor receptor 2 is currently being evaluated in clinical trials for oncology 
indications, with preliminary evidence of repeated dose safety and anti-tumor activity [4]. 
Benjamin Hackel et al. [5] describe a method for Fn3 library assembly whereby amino acid 
sequence and length diversity can be introduced into the BC, DE, and FG loops. Following 
structural and topological comparison of the Fn3 and TCR Vα loops (Figure 2-1), the sequences of 
homologous loops from Mart1-specific TCRs may be targeted for replacement onto the Fn3 
framework sequence. A library of Fn3 mutants containing loop grafts from these TCRs may be 
generated using an adaptation of the above polymerase chain reaction (PCR)-based assembly 
method. The techniques of yeast display and fluorescence activated cell sorting (FACS) may then 
enable the high-throughput screening and selection of positive binding clones.  
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Materials and Methods 
Reagents and strains 
The BirA-tagged and biotinylated extracellular domains of HLA-A2-Mart1 and HLA-A2-Ny-Eso-1 
were provided by the NIH Tetramer Facility. Yeast display Saccharomyces cerevisiae strain 
EBY100, yeast display plasmid pPNL6, yeast secretion strain YVH10, and yeast secretion plasmid 
pPNL9 were obtained from Pacific Northwest National Laboratory. All yeast display protocols, 
buffers, and reagents were used as previously described [6, 7]. Oligonucleotides were obtained from 
Integrated DNA Technologies, and PCR assembly primers were designed using DNAWorks from 
NIH’s Helix Systems [8]. Gene mutagenesis was performed by error-prone PCR as previously 
described [9], with nucleotide analogs from TriLink Biotechnologies. KOD Hot Start Polymerase 
from Novagen was used to PCR assemble gene inserts. The inserts have flanking 20-40 base pair 
overlaps with the desired cloning site in their respective, linearized plasmids. These were assembled 
into the appropriate plasmids using either yeast homologous recombination or Gibson cloning into 
TOP10 Escherichia coli cells. Reagents for Gibson cloning are as previously described [10], and 
constructs cloned into TOP10 competent cells were subsequently mini-prepped and transformed 
into yeast. Purification resins included HIS-select HF Nickel Affinity Gel from Sigma and 
StrepTactin Sepharose High Performance from GE Healthcare Life Sciences. Unless otherwise 
stated, all chemicals were from Sigma, and all E. coli strains from Life Technologies. Soluble 
protein expression was performed in 2.5 L Ultra Yield Flasks from Thomson.  Protein was 
concentrated in Amicon 3,000 Da MWCO centrifugal filters from EMD Millipore. DNA extraction 
was performed with kits from Qiagen. 
Loop grafts, error-prone mutagenesis, and library assembly 
The Fn3 library was constructed to produce the wild-type sequence in the framework regions and 
to graft the CDR1α, CDR2α, and CDR3α sequences of HLA-A2-Mart1-specific TCRs onto the 
BC, DE, and FG loops of Fn3, respectively. In addition, loop grafts from structurally 
characterized non-Mart1-specific TCRs, were included, especially where the loops specifically 
contact the MHC helices, in order to increase the paratope diversity of the library. Excision points 
for the loop grafts were determined by structural alignment of Fn3 to the TCR Vα domains, 
comparing the distances between Cα atoms of residue pairs to appropriately demarcate the loops 
(Figure 2-1). Specifically, the DNA encoding for amino acids 23–31 (DAPAVTVRY) was 
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replaced by DNA encoding for the CDR1α residues 24-32; the DNA for amino acids 51–56 
(PGSKST) was replaced by DNA encoding for the CDR2α residues 57-62; the DNA for amino 
acids 77–86 (GRGDSPASSK) was replaced by DNA encoding for the CDR3α residues 107-117. 
All residue numbers for TCRs correspond to the IMGT numbering designated for TRAV gene 
sequences. Double-stranded DNA corresponding to these loop fragments (with 30 base pairs of 
homology to adjoining framework regions), as well as double-stranded DNA corresponding to the 
constant framework regions, were prepared from pairs of complementary oligonucleotides by 
overlap extension PCR. The full-length Fn3 library was assembled as previously described [5], 
resulting in a small library ( < 1000 unique clones) of Fn3-TCR chimeras. 
Error-prone PCR directed solely at the solvent-exposed loops of this library was used to focus 
diversity on the likely paratope. Fn3 genes were constructed with conserved wild-type framework 
sequence and randomly mutated loops from the pool of Fn3-TCR chimeras assembled above. 
Error-prone PCR of the loop regions was performed via three separate 50 µL reactions with 20 
mM 8-oxo-deoxyguanosine triphosphate and 20 mM 2'-deoxy-p-nucleoside-5'-triphosphate and 
primers flanking the BC, DE, and FG loops. The reaction mixtures were denatured at 94°C for 3 
min, cycled 15 times at 94°C for 45s, 60°C for 30s, and 72°C for 90s, and finally extended at 
72°C for 10 min. Multiple preliminary mutagenesis reactions of the wild-type plasmid were 
conducted at different nucleotide analog concentrations. Sequence analysis and comparison to a 
wild-type framework indicate that the aforementioned conditions produce one to five amino acid 
mutations per loop. The PCR products were purified by agarose gel electrophoresis and each 
amplified in four 100-µL PCR reactions containing 1× Taq buffer, 2 mM MgCl2, 1 µM of each 
primer, 0.2 mM (each) dNTPs, 4 µL of error-prone PCR product (of 40 µL from gel extraction), 
and 2.5 U of Taq DNA polymerase. The reactions were thermally cycled at the same conditions 
except that 35 cycles were used. The full-length Fn3 library was then assembled from the 
mutagenized loop fragments and constant framework fragments similarly to the non-mutagenized 
library above. 
Yeast display, flow cytometry, and sorting 
Yeast displayed protein was expressed at 20ºC and 250 RPM for 16 hours. Displayed protein was 
incubated with biotinylated monomeric HLA-A2-Mart1 or HLA-A2-Ny-Eso-1, or tetrameric 
peptide-MHC prepared by incubating streptavidin–fluorophore (R-phycoerythrin, AlexaFluor488; 
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Invitrogen, Carlsbad, CA) with biotinylated pMHC in a 1:4 ratio (four equal additions of 
fluorophore, 10 min in between additions, covered from light at room temperature) in phosphate-
buffered saline (PBS). Flow cytometry was performed on a BD Biosciences FACSCalibur, and 
data was analyzed with FlowJo from Tree Star. 50,000 cell counts were collected for each binding 
analysis experiment. All yeast display experiments were performed in PBS with 0.1% w/v bovine 
serum albumin (PBSF) buffer as previously described [11]. Libraries were constructed by high 
efficiency yeast electroporation [7]. FACS was performed on the MoFlo XDP instrument from 
Beckman Coulter using polypropylene BD Falcon FACS tubes.  
Measurement of Kd in yeast display 
Affinity titrations to determine the equilibrium dissociation constant (Kd) for given clones were 
performed as previously described [12]. All incubations were performed while nutating at room 
temperature. Quenched samples were placed on ice in a 4ºC cold room. All work with cold samples 
was performed at 4ºC with chilled tips and a dedicated cold room centrifuge. Samples were handled 
in 1.5 mL Eppendorf tubes, and then transferred to a Nunc polypropylene 96-well V-bottom plate 
prior to addition of secondary reagents for ease of handling and standardization between samples. 
Prior to flow cytometry analysis, samples were spun down and kept as pellets on ice, covered from 
light. Immediately prior to analysis, individual samples were resuspended in 0.5 mL of PBSF and 
transferred to a polystyrene BD Falcon FACS tube for loading. 20,000 cell counts were collected 
for each sample in titration assays. Analysis was performed in GraphPad Prism version 6.0d for 
OSX 10.9 from GraphPad Software. Kd was fit to the Michaelis-Menten model. 
Expression of soluble anti-Mart1 Fn3 
Fn3 clones were expressed in YVH10 yeast secretion culture. YVH10 transformed with an Fn3 
construct in pPNL9 with a 6×HIS tag were grown overnight in 6L of SDCAA–Ura. This was spun 
down and transferred to YPGR media (1% yeast extract, 2% bacto peptone, 2% galactose, 2% 
raffinose, 0.1% dextrose; denoted in w/v, yeast media components from BD Biosciences, sugars 
from Sigma) with penicillin-streptomycin from Life Technologies. This culture was expressed at 
20ºC, 200 RPM, for 48 hours. Pellets were spun down and discarded twice, and the supernatant was 
ammonium sulfate (VWR) precipitated at 80% salt. Precipitate was resuspended in YVH10 
binding/wash buffer (300 mM NaCl, 20 mM sodium phosphate, pH 7.8, 0.05% tween 20, 2.5% 
glycerol, 10 mM imidazole) and loaded onto HIS-select resin. After washing with the same buffer, 
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samples were eluted in YVH10 elution buffer (300 mM NaCl, 20 mM sodium phosphate, pH 7.8, 
0.05% tween 20, 2.5% glycerol, 200 mM imidazole), concentrated, and run over an analytical 
Superdex-75 column from Amersham Pharmacia on the ÄKTA FPLC system. Sample volume was 
0.5 mL, run at 0.5 mL/min in PBS. Typical yields were 0.1 mg/L from yeast secretion culture. 
Characterization of soluble anti-Mart1 Fn3 by surface plasmon resonance 
Surface plasmon resonance (SPR) experiments were performed as previously described [13] 
using a Biacore T200 instrument with CM5 sensor chips and HBS-EP+ buffer (GE Healthcare) at 
25°C. Streptavidin was first coupled to the sensor surface using amine coupling, and biotinylated 
HLA-A2-Mart1 was then immobilized at different densities to flow cells 2 through 4 of the 
streptavidin coated chip. Soluble anti-Mart1 Fn3 was flowed over the chip at twofold serial 
dilutions ranging from 1500 nM to 12 nM, with a buffer-only control to establish a baseline. Data 
were corrected for bulk solvent effects using a flow cell containing immobilized streptavidin 
only. Flow rates were 5 µl/min. Data were processed with Biacore T200 Evaluation Software (GE 
Healthcare). 
Reversion clone construction 
Reversion of engineered loops of anti-Mart1 Fn3 to the wild-type Fn3 sequence was achieved by 
PCR assembling the wild-type loop fragments with 30 base pairs of homology to the flanking 
framework regions, amplifying the plasmid backbone minus the targeted loop segment (round the 
horn PCR), and then assembling the backbone and fragment pairs by Gibson assembly [14]. 
Because the backbone is amplified from the anti-Mart1 Fn3 DNA contained in the pPNL6 
backbone, assembly results in a complete gene within a yeast display vector. 
Structural Modeling of anti-Mart1 Fn3 
A structural model of the interaction between the anti-Mart1 Fn2 and HLA-A2-Mart1 was 
constructed using the AnchoredDesign package within the Rosetta 3.3 software suite [15]. This 
package was designed to model docked structures interacting through flexible surface loops 
where there is evidence for a particular binding mode. In this case, the FG loop of the Fn3 
scaffold (PDB: 1fna) is aligned to the residues from the CDR3α of the DMF5 TCR that contact 
HLA-A2-Mart1 (PDB 3qdg) and are also contained in the anti-Mart1 Fn3. These residues are 
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called the anchor region, and form the basis for the hypothesized binding interaction between 
HLA-A2-Mart1 and the anti-Mart1 Fn3. Starting from this structure, and holding the anchor 
region constant, the FG loop of Fn3 is remodeled and minimized, and the side chains are 
repacked, as previously described [16]. The models were analyzed by calculating the Rosetta 
score, per-atom solvent accessible surface area, and shape complementarity, all using the Rosetta 
software package. 
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Results 
Identification of a dominant clone 
The error-prone library of Fn3 genes was incorporated into a yeast surface display system by 
homologous recombination with the pPNL6 vector incorporating an N-terminal Aga2 protein for 
display on the yeast surface and a C-terminal c-myc epitope for detection of full-length Fn3. 
Library transformation yielded 5 × 106 yeast transformants. A library size of 108 was expressed 
and subjected to five sequential fluorescence-activated cell sorting (FACS) sorts with decreasing 
concentrations of HLA-A2-Mart1 tetramer. Sorting against 200 nM for the first two sorts and 100 
nM for the final three sorts, the top 1-5% of each population for both antigen binding and c-myc 
expression levels was collected for culture outgrowth (Figure 2-2). Each round was monitored by 
sequencing 10 clones at each step. By round five, the library converged upon a dominant clone 
with the sequence of PFTDSAIYGH in the BC loop, VTGSGS in the DE loop, and 
NFGGGKLIFGQ in the FG loop (Table 2-1).  
Remarkably, the sequence of the FG loop contains no mutations relative to the CDR3α from TCR 
DMF5, suggesting strong selective pressure for the wild-type loop sequence. Structural analysis 
of this loop in the context of the DMF5 TCR (PDB 3qdg) demonstrates that the loop residues 
exclusively contact amino acids of the α2-helix of HLA-A2. A structural model determined by 
computationally grafting the selected loop sequences onto the Fn3 framework, preserving the 
contacts made between the DMF5 CDR3α with HLA-A2-Mart1, suggests that peptide selectivity 
is likely mediated by Tyr-30 of the engineered BC loop, which is positioned to contact Ile-5 of 
the Mart1 peptide (Figure 2-3). The engineered variant- anti-Mart1 Fn3- was selected for further 
experimental characterization and analysis. 
Binding and selectivity of anti-Mart1 Fn3 in yeast display 
Yeast displaying anti-Mart1 Fn3 were incubated with 100 nM HLA-A2-Mart1 tetramer or 100 
nM HLA-A2-Ny-Eso-1 tetramer to determine the relative affinity of the clone to HLA-A2 
presenting two different peptides. At this concentration of tetramer, anti-Mart1 Fn3 exhibits clear 
binding to HLA-A2-Mart1 and no detectable binding to irrelevant antigen (Figure 2-4). These 
data suggest that anti-Mart1 Fn3 is, in fact, selective for the Mart1 peptide.  
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An affinity titration was performed to determine the Kd at equilibrium. Yeast displaying anti-
Mart1 Fn3 were incubated with varying concentrations of HLA-A2-Mart1 tetramer (0–2000 nM) 
for two hours. This experiment is not designed to determine the monovalent binding of anti-
Mart1 Fn3 to HLA-A2-Mart1, because antigen is multivalently coupled to streptavidin-
fluorophore (maximum valency of four). However, the binding affinity to tetramer was measured 
to be 927 ± 280 nM (Figure 2-5). 
Characterization of soluble anti-Mart1 Fn3 by surface plasmon resonance 
To confirm that anti-Mart1 Fn3 functions outside of display format, S. cerevisiae was used as a 
host to express and secrete the protein into the culture medium. Soluble anti-Mart1 Fn3 appears to 
be monomeric by comparison to FPLC standards (Figure 2-6). The purified protein was 
subsequently characterized for binding to HLA-A2-Mart1 monomer by surface plasmon 
resonance. Streptavidin was first coupled to the sensor chip, followed by injection and binding of 
biotinylated HLA-A2-Mart1 monomer (Figure 2-7). Varying concentrations of anti-Mart1 Fn3 
were injected in order to obtain a binding isotherm and determine an equilibrium dissociation 
constant. However, such a determination was not possible because binding was not measured at 
sufficiently high concentrations of anti-Mart1 Fn3. Furthermore, whenever quantities of anti-
Mart1 Fn3 were reduced in volume to a concentration exceeding the upper limit of this 
experiment, a visible precipitate materializes, and concentrations do not increase as measured by 
absorbance at 280 nm. This observation suggests that anti-Mart1 Fn3 is not well soluble in PBS. 
Nevertheless, the SPR data does demonstrate binding of soluble anti-Mart1 Fn3 to HLA-A2-
Mart1, and that this binding exhibits a concentration dependence (Figure 2-7). Furthermore, the 
SPR trace qualitatively demonstrate that the binding kinetics exhibit a fast on-rate and fast off-
rate, which are analogous to the kinetics of association and dissociation of the wild-type DMF5 
TCR [2], suggesting a potentially similar mechanism of binding for the two molecules. 
Reversion to wild-type loops 
In an attempt to improve the solubility of anti-Mart1 Fn3 while retaining binding affinity and 
selectivity to HLA-A2-Mart1, the BC, DE, and FG loops were independently restored to their 
wild-type Fn3 sequence. Because Fn3 is known to be highly stable and well soluble in standard 
buffers [3], and because the loss of solubility in anti-Mart1 Fn3 is ostensibly due to the mutated 
and atypical length loops, the reversion of one or more loops to their original sequences may 
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recover the solubility properties characteristic of wild-type Fn3. However, when the reversion 
clones are assayed for binding to HLA-A2-Mart1 tetramer by yeast display, no detectable binding 
relative to anti-Mart1 Fn3 is observed (Figure 2-8). Thus, no further characterization of the 
reversion clones was pursued.  
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Discussion 
In theory, Fn3 is an ideal scaffold target for TCR domain transfer across many criteria. For 
instance, it is extremely thermostable with a reported Tm of 88°C [17], monomeric, contains no 
cysteines, and is produced at high yields in E. coli. However, it is known that diversification of 
the BC, DE, and FG loops have a substantial deleterious effect on thermodynamic stability [5]. 
Although anti-Mart1 Fn3 is highly expressed in yeast display format, and binds selectively to 
HLA-A2-Mart1 in both yeast display and as a soluble protein, its utility as a molecular 
recognition agent is clearly encumbered by its poor solubility. As no other region of the protein 
differs from the wild-type Fn3 sequence, the loop regions are implicated in the poor solubility of 
anti-Mart1 Fn3. It may be possible that only a subset of residues in one or more loops contribute 
to its poor solubility; however, all loops appear to be required for binding, as reversion of any one 
loop to its wild-type sequence ablates binding affinity for HLA-A2-Mart1. The computed 
structural model suggests that MHC-restriction is mediated by the FG loop, while peptide 
selectivity is mediated by Tyr-30 of the BC loop (Figure 2-3). Notably, the DE loop is not 
predicted to make any contacts with antigen. However, during multi-loop diversification, selected 
sequences must provide not only proper intermolecular contacts for binding but also appropriate 
intramolecular contacts. 
The apparent low affinity of anti-Mart1 Fn3 is expected, given that the assumed binding domain 
is derived from a TCR. In particular, the DMF5 TCR is reported to bind to HLA-A2-Mart1 with a 
Kd of 6 µM [2]. Because it is relatively straightforward, once a baseline of affinity has been 
established, to engineer a clone that expresses in yeast display format for greater affinity, the low 
affinity of anti-Mart1 Fn3 is not discouraging. For instance, multiple further rounds of directed 
evolution through focused or random mutagenesis could potentially increase affinity by several 
orders of magnitude [5]. Indeed, the computed structural model may inform efforts to mutagenize 
anti-Mart1 Fn3 in a site-directed manner, in order to increase its affinity for HLA-A2-Mart1 
without sacrificing its peptide selectivity [18]. However, the persistence of poor solubility could 
be problematic, as a lack of selective pressure on the library for solubility could result in the 
continued selection of poorly soluble clones. 
The low expression and solubility of anti-Mart1 Fn3 may be driven by either loss of 
thermodynamic stability following parallel grafting of TCR loop sequences, or by the presence of 
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aggregation-prone sequence elements. Indeed, because TCRs are physiologically expressed as 
transmembrane proteins, there is no selective pressure toward sequences amenable for soluble 
production. The loops grafted onto anti-Mart1 Fn3, though, are derived from TCRs that have 
been produced solubly in sufficient yields for crystallography, so the loop sequences may not 
themselves be susceptible to aggregation. In the context of a non-native Fn3 framework, however, 
the TCR sequences may impart a tendency to oligomerize. Additionally, although the solvent-
exposed loop of Fn3 are more likely to tolerate sequence diversity than framework regions, the 
combination of multiple destabilizing alterations to Fn3 spawned from poorly stable TCRs may 
negatively impact the thermodynamic stability of the scaffold. In fact, solvent-exposed loops of 
several proteins have been determined to contain hotspots for both stabilizing and destabilizing 
mutations [19], and the imposition of non-native loop lengths onto the Fn3 framework may 
further promote destabilization. Because the relatively conservative error-prone PCR procedure 
employed in this study failed to recover adequate biophysical properties, it is clear that 
exceptional care must be given to promote stability and solubility of TCR-based chimeric 
libraries. 
A potential solution to this challenge going forward could be to employ a method that would 
enable selection for protein solubility. One such method is the technique of secretion-and-capture 
yeast display, whereby the Fn3 library would be secreted by the host yeast strain before being 
anchored to the yeast cell wall by a strong, non-covalent interaction [20]. More specifically, the 
Fn3 library is genetically fused to a biotin acceptor peptide, to which heterologously co-expressed 
BirA enzyme site-selectively fuses a biotin moiety. Before library expression is induced, the 
surface of the yeast cells is covalently labeled with NHS-PEG-biotin and avidin. When the 
biotinylated Fn3 clones are secreted into the extracellular space, they strongly bind the surface-
localized avidin, so that the clones are displayed on the surface of the yeast. Because the 
individual clones must be solubly secreted before they are surface-anchored, this method 
incorporates a selective pressure for the protein of interest to remain stable in solution. Thus, a 
potential advantage of this method is more efficient conversion from display to soluble 
production formats [20]. Combining this technique with a more comprehensive method of 
mutagenesis, including whole gene error-prone PCR [5], may increase the likelihood of selecting 
for soluble clones. 
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Another potential means of identifying clones that can be solubly produced may simply be to 
increase the hit rate of the library. Indeed, the size of the transformed library in this study (5 × 
106) is rather small relative to typical yeast display campaigns reported [21], which may be orders 
of magnitude larger. Increasing the size of the library concurrently increases the number of 
binders present within the library, and selecting for these binders would yield multiple hits. These 
hits can subsequently be evaluated for solubility; the greater the number of hits that can be 
evaluated, the greater the likelihood of identifying a subset of clones that may be solubly 
produced. 
A noteworthy consequence of this study is the discovery of an Fn3 clone comprising a wild-type 
CDR3α loop sequence in the FG loop. This loop, in the context of the DMF5 TCR, contributes to 
interactions with HLA-A2; the lack of mutations to the loop in anti-Mart1 Fn3 suggests that the 
FG loop adopts an analogous binding mode. In particular, the FG loop may anchor anti-Mart1 
Fn3 to the α2-helix of HLA-A2 in a manner that positions the BC loop to contact the displayed 
peptide. It is intriguing to observe that the residues grafted from Vα domains can govern binding 
of anti-Mart1 Fn3 in the absence of any interactions mediated by Vβ. Importantly, though, the FG 
loop of anti-Mart1 Fn3 may provide a platform for future efforts to engineer Fn3-based binders to 
novel pMHC targets. In particular, by constructing libraries such that the FG loop is fixed to this 
specific sequence, and such that the BC and DE loops are diversified (i.e. with degenerate 
nucleotides), such libraries may bias interactions toward a binding mode that promotes peptide 
selectivity yet enables selection of clones that bind novel peptide antigens. 
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Conclusion 
This study establishes that a Mart1-targeted library of diversified Fn3-TCR chimeras can yield a 
clone with measurable binding to HLA-A2-Mart1. These findings are notable in that they 
establish that the binding domains of TCRs, which typically express poorly in yeast display 
format [22], can be transferred to a homologous scaffold that displays efficiently. Furthermore, 
the resulting libraries are capable of producing clones that are peptide-selective. The latter finding 
is significant because a top hit from a naïve (synthetic or pre-immune) library would not a priori 
be expected to be peptide-selective, as there is no rationale for the selection of clones targeting 
the peptide epitope rather than any other molecular surface of the peptide-MHC molecule. 
However, the fact that the Fn3-TCR library was generated from TCRs known to make molecular 
contacts to peptides within the MHC groove biases the library toward peptide-selectivity. 
Because any top hits are already verified to display efficiently in yeast, they may form the basis 
for further diversification in order to engineer for greater affinity and, potentially, solubility 
(Figure 2-9). In contrast, the TCR clones from which the original Fn3-TCR library is derived are 
naturally recalcitrant to display formats and, accordingly, may not be amenable to further 
engineering.  
Furthermore, the hypothesized role of the anti-Mart1 Fn3 FG loop in modulating binding to 
HLA-A2 enables the construction of Fn3 libraries, informed by structural models, that may yield 
selective binders against novel peptide epitopes. Thus, this work represents a promising approach 
to the generation of proteins with TCR-like selectivity for cognate peptide-MHC antigens. In 
order to increase the chances of success in future work exploiting this method, larger libraries 
may need to be generated (in order to increase the number of evaluable hits), and methods such as 
secretion and capture yeast display should be employed (in order to select for clones that transfer 
effectively from display to soluble format). 
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1
Figure 2-1. Structural alignment of Fn3 (gray) to the TCR Vα domain (blue). 
Recombination points for library generation are chosen at positions of homologous 
residue pairs on the BC loop and CDR1α (A), and on the FG loop and CDR3α (B). 
Structurally, distances between recombination endpoints on corresponding loops are 
roughly equivalent. 
2
A B 
  
37 
 
 
 
Loop Sequence Source TCR WT TCR sequence WT Fn3 sequence 
BC PFTDSAIYGH TCR 1G4 SFTDSAIYNY DAPAVTVRYY 
DE VTGSGS TCR JM22 VTGGEG PGSKST 
FG NFGGGKLIFGQ TCR DMF5 NFGGGKLIFGQ GRGDSPASSK 
 
 
 
 
 
 
  
Table 2-1. Loop sequences of dominant clone anti-Mart1 Fn3. Amino acids that differ 
relative to the parental TCR sequence (resulting from error-prone PCR) are highlighted in 
red. 
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Figure 2-2. FACS plots for sequential sorts (A-D) 
of the Fn3 library against decreasing concentrations 
of HLA-A2-Mart1. The x-axes track the degree of 
antigen binding, reported by the fluorophore PE. (E) 
Overlaid histograms comparing the extent of antigen 
binding across subsequent rounds; the red histogram 
corresponds to the first round and the green 
corresponds to the fourth. 
C 
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Figure 2-3. (A) Crystal structure of the DMF5 TCR alpha chain in complex with HLA-
A2-Mart1. CDR3α (magenta) mediates interaction with the α2-helix of HLA-A2. (B) In 
the structural model of the interaction between anti-Mart1 Fn3 and HLA-A2-Mart1, the 
contacts mediated by the DMF5 CDR3α are assumed to be conserved, positioning Tyr-
30 of the BC loop to contact Ile-5 of the Mart1 peptide (C). 
A B 
C 
  
40 
  
 
 
 
 
 
Figure 2-4. FACS plots demonstrating 
the selectivity of anti-Mart1 Fn3 binding 
in yeast display to (A) HLA-A2-Mart1 
over (B) irrelevant pMHC antigen HLA-
A2-Ny-Eso-1. The x-axes track the degree 
of antigen binding, reported by the 
fluorophore PE. (C) Overlaid histograms 
comparing the extent of binding to both 
antigens further illustrate the degree of 
selectivity. 
A B 
C 
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Figure 2-5. Equilibrium affinity titration of HLA-A2-Mart1 tetramer against displayed 
anti-Mart1 Fn3. 
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A 
B 
Figure 2-6. (A) Gel filtration profile of soluble anti-Mart1 Fn3. The major peak 
indicates the presence of soluble aggregate, while the minor peak corresponds to the 
expected monomeric profile. (B) Standards from the AKTA manual for comparison. 
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Figure 2-7. SPR characterization of anti-Mart1 Fn3. (A) Streptavidin is immobilized to 
the sensor chip by amine coupling. (B) Biotinylated HLA-A2-Mart1 is bound to the 
streptavidin chip to 1200 RUs. (C) Response following injections of increasing 
concentrations of anti-Mart1 Fn3 demonstrates dose-dependent binding. 
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Figure 2-8. Reversions of anti-Mart1 Fn3 loops to their respective wild-type Fn3 
sequence, evaluated for binding to HLA-A2-Mart1 by yeast display. The y-axis tracks 
binding to tetramer, while the x-axis reports Fn3 expression by c-myc staining. All 
clones express at similar levels. However, while (A) anti-Mart1 Fn3 binds HLA-A2-
Mart1, reversions to wild-type (B) BC, (C) DE, and (D) FG Fn3 loops ablates binding 
to tetramer.   
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Figure 2-9. Implications of this study for future efforts to engineer anti-pMHC, 
Fn3-based binders. Robust expression in yeast display and verified pMHC 
selectivity allow Fn3-TCR chimeras such as anti-Mart1 Fn3 to serve as starting 
scaffolds for further engineering. 
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C h a p t e r  3  
CONSTRUCTION AND SCREENING OF 4D5-TCR LIBRARIES ENABLES THE 
DISCOVERY OF PEPTIDE-MHC-SELECTIVE CLONES 
Abstract 
The relative success of the TCR-to-Fn3 domain swapping motivates the question of whether TCR 
binding domains may be successfully transferred to homologous scaffolds other than Fn3. The 
Fab fragment of antibodies is a particularly compelling candidate for such an investigation, 
because of its extensive validation as a molecular recognition scaffold, and because of its more 
faithful homology to the TCR framework. To this end, the 4D5 scaffold is selected as a target for 
binding domain transfer of HLA-A2-Mart1- and HLA-A2-Ny-Eso-1-specific TCRs. In order to 
rationally transfer the CDR loops of these TCRs to 4D5, a library assembly method was 
developed, guided by the previous TCR-to-Fn3 study and by established approaches for 4D5 loop 
diversification. Similar to the TCR-to-Fn3 study, successful transfer of binding properties 
entailed the construction of a mutagenized library. Subsequent screens and selections in yeast 
display led to the identification of clones selective for HLA-A2-Mart1 and HLA-A2-Ny-Eso-1. 
Expression and further characterization of the clones in soluble format demonstrated a reduction 
in yield and solubility relative to wild-type 4D5. However, binding measurements evaluated by 
surface plasmon resonance (SPR) affirmed the functionality of a Mart1-selective 4D5 variant. 
The findings of this study, concurrent with the implications of Chapter 2, suggest that the grafted 
TCR loops, while conferring binding selectivity, may also engender biophysical deficiencies.  
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Introduction 
Chapter 2 provides a proof of concept for the domain transfer of paratopes from TCRs onto the 
homologous protein scaffold Fn3. Although Fn3 is a convenient molecular scaffold to implement as 
a target of TCR domain transfer, because of its high thermostability and purported ease of 
expression in E. Coli, these advantages did not transfer well to clones selected from a library 
derived from TCR loop sequences. Furthermore, while the contribution of the Vα domain of HLA-
A2-Mart1-specific TCRs to peptide binding appears to be sufficient for transfer of selectivity to 
Fn3, the Vα and Vβ domains of TCRs both provide molecular contacts to the peptide epitope. 
Indeed, the Vα and Vβ domains are typically positioned to contact the N-terminal and C-terminal 
domains of the peptide within the MHC groove, respectively. Thus, in order to universally achieve 
TCR-like specificity, it may be important to utilize a scaffold that can acquire paratopes from both 
Vα and Vβ domains of TCRs.  
The impact of TCR loop sequences on the solubility of Fn3 also underscores the importance of loop 
sequence on the biophysical properties of the scaffold. Although Fn3 has been used successfully to 
engineer binders against a variety of targets, thorough studies on the precise impact of loop 
mutations accumulated at different positions, and on the impact of loop length diversity, are needed 
[1]. It has further been demonstrated that many variants generated by diversification of the BC, DE, 
and FG loops have substantially reduced thermodynamic stability [2]. With more insight into what 
positions can tolerate sequence diversity, and to what extent, more robust Fn3 libraries can be 
constructed, which may yield clones with improved biophysical characteristics. 
In contrast, the 4D5 framework, based on the trastuzumab Fab sequence, is an extensively validated 
scaffold for generating naïve libraries for molecular recognition [3]. Particularly, there is vast 
knowledge informing how libraries may be generated, guided by experimental data and by 
sequence diversity within the Fab gene family [4]. In Chapter 1, a rationale is proposed for 4D5 as a 
suitable scaffold for TCR binding domain transfer. Notably, homology of the variable light (VL) and 
variable heavy (VH) domains of 4D5 to the Vα and Vβ domains of TCRs, respectively, suggests that 
CDR grafting may endow 4D5 with the peptide specificity of TCRs. In Chapter 2, a library cloning 
method is described whereby sequence and length diversity can be introduced into certain loops of 
Fn3. By examining the homology of TCR loops to the 4D5 scaffold, and by exploiting existing 
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knowledge of mutagenic 4D5 libraries [5], the sequences of homologous loops may be targeted for 
replacement from TCRs onto the 4D5 framework sequence.  
I chose to validate the approach of TCR-to-4D5 domain swapping by engineering binders against 
HLA-A2-Mart126-35 and HLA-A2-Ny-Eso-1157-165. Specifically, HLA-A2-Mart1 is targeted by the 
TCRs MEL5 [6], DMF4, and DMF5 [7], and HLA-A2-NyEso-1 is targeted by the TCRs 1G4 and 
c58/c61 [8]. Libraries of 4D5 mutants containing loop grafts from these Mart1- and Ny-Eso-1-
specific TCRs may be generated by adapting the polymerase chain reaction (PCR)-based assembly 
method implemented in Chapter 2. The techniques of yeast display and fluorescence activated cell 
sorting (FACS) may then enable the high-throughput screening and selection of positive binding 
clones. 
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Materials and Methods 
Reagents and strains 
The BirA-tagged and biotinylated extracellular domains of HLA-A2-Mart1 and HLA-A2-Ny-Eso-1 
were provided by the NIH Tetramer Facility. Yeast display Saccharomyces cerevisiae strain 
EBY100, yeast display plasmid pPNL6, yeast secretion strain YVH10, and yeast secretion plasmid 
pPNL9 were obtained from Pacific Northwest National Laboratory. All yeast display protocols, 
buffers, and reagents were used as previously described [9, 10]. Oligonucleotides were obtained 
from Integrated DNA Technologies, and PCR assembly primers were designed using DNAWorks 
from NIH’s Helix Systems [11]. Gene mutagenesis was performed by error-prone PCR as 
previously described [12], with nucleotide analogs from TriLink Biotechnologies. KOD Hot Start 
Polymerase from Novagen was used to PCR assemble gene inserts. The inserts have flanking 20-40 
base pair overlaps with the desired cloning site in their respective, linearized plasmids. These were 
assembled into the appropriate plasmids using either yeast homologous recombination or Gibson 
cloning into TOP10 Escherichia coli cells. Reagents for Gibson cloning are as previously described 
[13], and constructs cloned into TOP10 competent cells were subsequently mini-prepped and 
transformed into yeast. Purification resins included HIS-select HF Nickel Affinity Gel from Sigma 
and StrepTactin Sepharose High Performance from GE Healthcare Life Sciences. Unless otherwise 
stated, all chemicals were from Sigma, and all E. coli strains from Life Technologies. Soluble 
protein expression was performed in 2.8 L glass culture flasks from Corning, using Freestyle 293 
Expression Medium from Life Technologies. Protein was concentrated in Amicon 10,000 Da 
MWCO centrifugal filters from EMD Millipore. DNA extraction was performed with kits from 
Qiagen. 
Loop grafts, error-prone mutagenesis, and library assembly 
The 4D5 library was constructed to produce the wild-type sequence in the framework regions and 
to graft the CDR1α, CDR3α, CDR1β, CDR2β, and CDR3β sequences of HLA-A2-Mart1- and 
HLA-A2-Ny-Eso-1-specific TCRs to the CDR-L1, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 
loops of 4D5, respectively. In particular, two libraries were generated: one corresponding to 
grafts from Mart1-specific TCRs and the other to grafts from Ny-Eso-1-specific TCRs. Excision 
points for the loop grafts were determined by sequence alignment of 4D5 and TCR V-domains, 
using previously defined boundaries for 4D5 CDR diversification to appropriately demarcate the 
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loops (Figure 3-1). The DNA encoding for CDR-L1 residues 27-34 was replaced by DNA 
encoding for the CDR1α residues 27-38. Similarly, the DNA for CDR-L3 residues 91-97 was 
replaced by DNA encoding for the CDR3α residues 107-115; DNA for CDR-H1 residues 27-35 
was replaced by DNA encoding for the CDR1β residues 27-38; DNA for CDR-H2 residues 50-59 
was replaced by DNA encoding for the CDR2β residues 55-67; DNA for CDR-H3 residues 99-
109 was replaced by DNA encoding for the CDR3β residues 107-117. All residue numbers for 
TCRs correspond to the IMGT numbering designated for TRAV gene sequences, and residue 
numbers for 4D5 correspond to indexing used in the PDB file 1n8z, utilizing the Chothia 
numbering scheme [14]. Double-stranded DNA corresponding to these loop fragments (with 30 
base pairs of homology to adjoining framework regions), as well as double-stranded DNA 
corresponding to the constant framework regions, were prepared from pairs of complementary 
oligonucleotides by overlap extension PCR. The full-length 4D5 library was assembled by 
extension of a previously described protocol [2], by adapting the assembly of the Fn3 gene from 
seven overlapping fragments to the assembly of the 4D5 gene from eleven overlapping fragments. 
Each library assembled resulted in a theoretical library size of approximately 1000 unique clones of 
4D5-TCR chimeras. 
Error-prone PCR directed solely at the solvent-exposed loops of these libraries was used to focus 
diversity on the likely paratope. 4D5 genes were constructed with conserved wild-type 
framework sequence and randomly mutated loops from the pool of 4D5-TCR chimeras assembled 
above. For each library, error-prone PCR of the loop regions was performed via five separate 50 
µL reactions with 20 mM 8-oxo-deoxyguanosine triphosphate and 20 mM 2'-deoxy-p-nucleoside-
5'-triphosphate and primers flanking the diversified CDR loops. The reaction mixtures were 
denatured at 94°C for 3 min, cycled 15 times at 94°C for 45s, 60°C for 30s, and 72°C for 90s, and 
finally extended at 72°C for 10 min. Multiple preliminary mutagenesis reactions of the wild-type 
plasmid were conducted at different nucleotide analog concentrations. Sequence analysis and 
comparison to a wild-type framework indicated the aforementioned conditions yield one to five 
amino acid mutations per loop. The PCR products were purified by agarose gel electrophoresis 
and each amplified in four 100-µL PCR reactions containing 1× Taq buffer, 2 mM MgCl2, 1 µM 
of each primer, 0.2 mM (each) dNTPs, 4 µL of error-prone PCR product (of 40 µL from gel 
extraction), and 2.5 U of Taq DNA polymerase. The reactions were thermally cycled at the same 
conditions except that 35 cycles were used. The full-length 4D5 libraries were then assembled 
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from the mutagenized loop fragments and constant framework fragments similarly to the non-
mutagenized library above. 
Yeast display, flow cytometry, and sorting 
Yeast displayed protein was expressed at 20ºC and 250 RPM for 16 hours. Displayed protein was 
incubated with biotinylated monomeric HLA-A2-Mart1 or HLA-A2-Ny-Eso-1, or tetrameric 
peptide-MHC prepared by incubating streptavidin–fluorophore (R-phycoerythrin, AlexaFluor488; 
Invitrogen, Carlsbad, CA) with biotinylated pMHC in a 1:4 ratio (four equal additions of 
fluorophore, 10 min in between additions, covered from light at room temperature) in phosphate-
buffered saline (PBS). Flow cytometry was performed on a BD Biosciences FACSCalibur, and 
data was analyzed with FlowJo from Tree Star. 50,000 cell counts were collected for binding 
analysis experiments. All yeast display experiments were performed in PBS with 0.1% w/v bovine 
serum albumin (PBSF) buffer as previously described [15]. Libraries were constructed by high 
efficiency yeast electroporation [10]. FACS was performed on the MoFlo XDP instrument from 
Beckman Coulter using polypropylene BD Falcon FACS tubes.  
Protein L Selection 
Magnetic protein L beads were produced using biotinylated protein L (Pierce) and magnetic 
streptavidin Dynabeads (Invitrogen). Specifically, 33 pmoles of biotinylated protein L was 
combined with 4×106 beads and 100 µL of PBSF and nutated at 4ºC for 1 hour. Magnetic beads 
were separated in a magnetic separation rack (New England Biolabs), and washed twice with PBSF. 
The protein L beads were then used to select for yeast expressing 4D5 clones that bind to protein L, 
using a magnetic bead selection method described previously [16, 17]. 
Measurement of Kd in yeast display 
Affinity titrations to determine the equilibrium dissociation constant (Kd) for given clone were 
performed as previously described [17]. All incubations were performed while nutating at room 
temperature. Quenched samples were placed on ice in a 4ºC cold room. All work with cold samples 
was performed at 4ºC with chilled tips and a dedicated cold room centrifuge. Samples were handled 
in 1.5 mL Eppendorf tubes, and then transferred to a Nunc polypropylene 96-well V-bottom plate 
prior to addition of secondary reagents for ease of handling and standardization between samples. 
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Prior to flow cytometry analysis, samples were spun down and kept as pellets on ice, covered from 
light. Immediately prior to analysis, individual samples were resuspended in 0.5 mL of PBSF and 
transferred to a polystyrene BD Falcon FACS tube for loading. 20,000 cell counts were collected 
for each sample in kinetic assays. Analysis was performed in GraphPad Prism version 6.0d for OSX 
10.9 from GraphPad Software. Kd was fit to the Michaelis-Menten model. 
Expression of soluble anti-Mart1 and anti-Ny-Eso-1 4D5 
4D5 clones were expressed in HEK293-6E mammalian secretion culture. The full light chain and 
Fab heavy chain sequence were subcloned separately into the mammalian expression vector pTT5 
(NRC Biotechnology Research Institute), with a C-terminal hexa-histidine tag on the heavy chain. 
The heavy chain and light chain vectors were mixed at a 1:1 ratio by mass, and the corresponding 
proteins were expressed transiently in suspension HEK 293-6E cells (NRC Biotechnology Research 
Institute) using BioT transfection reagent (Bioland Scientific). Specfically, 1 mg of combined DNA 
was added to 34 mL of sterile filtered PBS in a 50 mL canonical tube and mixed thoroughly, after 
which 1 mL of BioT was added. The mixture was briefly vortexed and added to 1 L of culture 
supernatant.  
Prior to transfection, cells are grown until they reach a density of 2×106 cells/mL, and are split to a 
density of 1×106 cells/mL immediately preceding transfection. Cultures are grown at 8% CO2, 
37ºC, 90 RPM, humidified atmosphere for 6 days after transfection. Pellets were spun down and 
discarded twice, and the supernatant was sterile filtered and loaded onto HIS-select resin. After 
washing with the same buffer, samples were eluted in elution buffer (300 mM NaCl, 20 mM 
sodium phosphate, pH 7.8, 0.05% tween 20, 2.5% glycerol, 200 mM imidazole), concentrated, and 
run over an analytical Superdex-75 column from Amersham Pharmacia on the ÄKTA FPLC 
system. Sample volume was 0.5 mL, run at 0.5 mL/min in PBS. Typical yields were 0.2 mg/L from 
mammalian secretion culture. 
Characterization of soluble anti-Mart1 4D5 by surface plasmon resonance 
Surface plasmon resonance (SPR) experiments were performed as previously described [18] 
using a Biacore T200 instrument with CM5 sensor chips and HBS-EP+ buffer (GE Healthcare) at 
25°C. Streptavidin was first coupled to the sensor surface using amine coupling, and biotinylated 
HLA-A2-Mart1 was then immobilized at different densities to flow cells 2 through 4 of the 
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streptavidin coated chip. Soluble Fab was flowed over the chip at twofold serial dilutions 
ranging from 9000 nM to 70 nM, with a buffer-only control to establish a baseline. Data were 
corrected for bulk solvent effects using a flow cell containing immobilized streptavidin only. 
Flow rates were 5 µl/min. Data were processed with Biacore T200 Evaluation Software (GE 
Healthcare). 
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Results 
Identification of dominant clones 
The error-prone libraries of 4D5 genes were incorporated into a yeast surface display system by 
homologous recombination with the pPNL6 vector incorporating an N-terminal Aga2 protein for 
display on the yeast surface and a C-terminal c-myc epitope for detection of full-length 4D5. 
Library transformation yielded 3 × 107 yeast transformants per library. Library sizes of 3 × 108 
per library were expressed and subjected to five sequential fluorescence-activated cell sorting 
(FACS) sorts with decreasing concentrations of HLA-A2-Mart1 tetramer or HLA-A2-Ny-Eso-1 
tetramer on the Mart1- and Ny-Eso-1-directed libraries, respectively. Sorting against 200 nM for 
the first two sorts and 100 nM for the final three sorts, the top 1-5% of each population for both 
antigen binding and c-myc expression levels was collected for culture outgrowth. Diversity of 
each round was monitored by sequencing 10 clones at each step. By round five, each library 
converged upon a dominant clone with the CDR loop sequences reported in Table 3-1. Although 
the clone isolated from HLA-A2-Ny-Eso-1 selection corresponds to a full-length 4D5 product, 
the dominant clone isolated from HLA-A2-Mart1 selection corresponds to a gene construct 
comprising only the VH domain of 4D5. This VH-only gene product is likely the result of excision 
of the VL segment and re-annealing to homologous Gly4/Ser linker-encoding regions that are 
present both upstream of the VL sequence and between the VL and VH sequences. This excision 
may have occurred in a subset of the clones through either the Gibson assembly step or yeast 
homologous recombination, during which constituent or endogenous exonucleases are capable of 
digesting the entire VL sequence. 
In order to isolate VL-containing 4D5 variants binding to HLA-A2-Mart1, the first round of the 
library was re-expressed and subjected to alternating rounds of protein L magnetic bead selection 
and FACS sorting with HLA-A2-Mart1 tetramer. After four total additional rounds of selection, a 
full-length 4D5 variant was isolated (Table 3-1).  
Notably, the CDR-H3 sequences of the full-length clones Ny.1 and Ma.2 contain no mutations 
and a single mutation relative to the CDR3β of parental TCRs, respectively, indicative of strong 
selective preference for the wild-type loop sequence. The CDR-H3 of antibodies is generally 
believed to play a dominant role in antigen recognition relative to other CDRs, inferred by the 
extent of sequence variability in natural antibodies and an abundance of structural information 
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revealing its contribution to interactions with antigen [19]. The conservation of wild-type TCR 
sequences in the CDR-H3 loops thus insinuates that the binding modes of these clones are similar 
to that of their parental TCRs. 
Binding and selectivity of engineered 4D5 variants in yeast display 
Yeast displaying Ny.1, Ma.1h, and Ma.2 were incubated with 100 nM HLA-A2-Mart1 tetramer 
or 100 nM HLA-A2-Ny-Eso-1 tetramer to determine the relative affinity of the clones to the same 
MHC allele presenting two different peptides. At this concentration of tetramer, Ny.1 exhibits 
clear binding to HLA-A2-Ny-Eso-1 and no detectable binding to irrelevant antigen (Figure 3-2). 
Similarly, Ma.1h exhibits clear binding to HLA-A2-Mart1 and no detectable binding to irrelevant 
antigen (Figure 3-2). These data suggest that both clones are peptide selective. In contrast, Ma.2 
exhibits weak binding to HLA-A2-Mart1 that is qualitatively greater than the detected binding to 
HLA-A2-Ny-Eso-1. The computed mean fluorescence intensity (MFI) of the positively stained 
population is approximately 30% higher for HLA-A2-Mart1 tetramer than the same concentration 
of HLA-A2-Ny-Eso-1 tetramer (MFI of 14.1 and 10.8, respectively). 
Affinity titrations were performed to determine the Kd at equilibrium for the three clones. Yeast 
displaying Ny.1 was incubated with varying concentrations of HLA-A2-Ny-Eso-1 tetramer (0–
2000 nM) for two hours, and yeast displaying Ma.1h, and Ma.2 were incubated with varying 
concentrations of HLA-A2-Mart1 tetramer (0–2000 nM) for two hours. This experiment is not 
designed to determine the monovalent binding to pMHC antigens, as antigen is multivalently 
coupled to streptavidin-fluorophore (maximum valency of four). However, the binding affinities 
to cognate pMHC tetramer were measured to be 377 ± 86 nM for Ny.1, and 1088 ± 20 nM for 
Ma.2 (Figure 3-3). 
Characterization of soluble Ma.2 by surface plasmon resonance 
To confirm that the engineered 4D5 variants functions outside of display format, HEK293-6e 
cells were used as a host to express and secrete Ny.1 and Ma.2 in Fab format into the culture 
medium. Although Ny.1 did not express at appreciable yields in the culture supernatant, Ma.2 did 
express at quantifiable yields. Soluble Ma.2 Fab runs at a size consistent with that of a full-length 
Fab by comparison to FPLC standards (Figure 3-4).  
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The purified protein was subsequently characterized for binding to HLA-A2-Mart1 monomer by 
surface plasmon resonance. Streptavidin was first coupled to the sensor chip, and was followed 
by binding of biotinylated HLA-A2-Mart1 monomer, as described in Chapter 2. Varying 
concentrations of Ma.2 Fab were injected in order to obtain a binding isotherm and determine 
equilibrium dissociation. However, such a determination was not possible because binding was 
not measured at sufficiently high concentrations of Ma.2. Furthermore, whenever quantities of 
Ma.2 were reduced in volume to a concentration exceeding the upper limit of this experiment, a 
visible precipitate materializes, and concentration does not increase as measured by absorbance at 
280 nm. This observation suggests that Ma.2 Fab is not well soluble in PBS. Nevertheless, the 
SPR data does demonstrate binding of soluble Ma.2 Fab to HLA-A2-Mart1, and that this binding 
exhibits a concentration dependence (Figure 3-5). Furthermore, the SPR trace qualitatively 
demonstrate that the binding kinetics exhibit a fast on-rate and fast off rate, which are analogous 
to the kinetics of association and dissociation of the wild-type DMF5 TCR [7], suggesting a 
potentially similar mechanism of binding for the two molecules. 
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Discussion 
The 4D5 scFv framework is well established as a scaffold for library generation and for 
molecular recognition to a variety of targets [5]. Moreover, such engineering has led to the 
identification of soluble targeting molecules demonstrating satisfactory biophysical profiles [20]. 
The multitude of work in engineering the scaffold has yielded standardized methods for 
introducing diversity into the various CDR loops. Additionally, 4D5 is widely used as a scaffold 
for the grafting of murine antibody sequences, validating its utility as a target for domain transfer 
[21]. 4D5 is, in principle, a canonical scaffold target for TCR domain transfer, as the close 
homology of the Fab and TCR scaffolds suggest that CDR loops may be transferred in a way that 
preserves the integrity of the binding domain. However, the relatively low thermodynamic 
stability of scFv scaffolds may adversely affect the evolvability of the domain in the context of 
TCR binding domain transfer [22]. In particular, the proportion of clones exhibiting acceptable 
solubility and thermodynamic stability may diminish considerably as broader diversity is 
introduced into the loop regions [23]. 
The deleterious effect of extensive loop modifications on the biophysical characteristics of 
engineered 4D5 variants is evidenced by the low expression yields of clones Ny.1 and Ma.1h, and 
by the poor solubility of Ma.2. In effect, despite their demonstrated expression and selective 
binding to cognate peptide-MHC antigens in yeast display format, these molecules have limited 
use as soluble reagents. The introduction of non-native TCR loop sequences onto the framework 
of 4D5 may prompt the loss of solubility and expression of Ma.2 by a variety of mechanisms. For 
instance, a decrease in thermodynamic stability may arise from loop graft sequences driving the 
energetics of Ma.2 protein folding or dynamics from the native 4D5 conformation toward an 
aggregation-prone state. The TCR sequences may provoke such instability generally, or 
specifically within the context of the atypical 4D5 framework; the latter account is more likely in 
light of the reported soluble expression of the DMF5 TCR [7]. For instance, unfavorable 
interactions, particularly among CDR-L3 and CDR-H3 residues, may disrupt the 4D5 VH-VL 
interface and expose hydrophobic patches, triggering aggregation [24]. Conversely, loss in 
solubility may also result from the presence of sequence epitopes within Ma.2 loops that promote 
nonspecific interactions, although this is less probable given the sequences are derived from a 
palpably well-behaved TCR. Although in Chapter 2, purification of soluble anti-Mart1 Fn3 
revealed the likely presence of a soluble oligomeric state, the FPLC chromatogram of Ma.2 
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indicates a single species corresponding to the 4D5 Fab (Figure 3-4). Accordingly, the poor 
solubility of Ma.2 may arise from a different mechanism than that causing the poor solubility of 
anti-Mart1 Fn3. These finding affirm that, although solvent-exposed loops of scaffolds such as 
4D5 and Fn3 are generally tolerant of diverse sequences, modifications of such domains may 
unexpectedly impair the general biophysical fitness of these proteins [25]. 
In addition to poor solubility, Ma.2 exhibits an apparently low affinity for HLA-A2-Mart1. Such 
weak binding may be attributed to the fact that the putative binding domain of Ma.2 is derived 
from the DMF5 TCR, which binds to HLA-A2-Mart1 with a Kd of 6 µM [7]. By itself, the low 
binding affinity of a 4D5 variant is quite surmountable, as additional rounds of focused or random 
mutagenesis may improve the affinity by several orders of magnitude [2]. Indeed, such 
engineering is feasible for the 4D5 scaffold due to its pronounced expression in yeast display 
format, which enables the continued enrichment of higher affinity clones from mutagenized 
libraries. However, the lack of selective pressure on the library for adequate expression yields and 
solubility may perpetuate the selection of clones exhibiting undesirable biophysical 
characteristics. 
In future studies, selection methods that incorporate a selective pressure or concurrent screen for 
protein solubility will be critical to attaining engineered variants that are useful as soluble 
reagents. Secretion-and-capture yeast display, in which a 4D5 library could be secreted by the 
host yeast strain before being anchored to the yeast cell wall by a strong, non-covalent 
interaction, is an example of such a system [26]. Another potential route would be to establish 
spatial separation of single yeast cells secreting individual 4D5 clones, namely by using a 
microfluidic device in which individual chambers contain immobilized antigen, before screening 
for binding of single clones [27, 28]. Such microfluidic techniques have been used, for example, 
in the profiling of cytokine secretions from primary T cells, and allow up to 104 cells per 
experiment to be evaluated [29, 30]. In both cases, the protein of interest must be solubly secreted 
before binding may be assayed, requiring a protein to remain stable in solution in order to endure 
selection; as a result, such methods are more likely to effect efficient conversion to soluble 
production formats.  
Concurrent with a more appropriate selection system, the execution of TCR-to-4D5 binding 
domain transfer may also benefit from the screening of larger libraries, permitting the inspection 
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of a greater breadth of sequence space. Specifically, library size may be enlarged either by 
increasing the throughput of yeast transformations or by implementing optimized transformation 
protocols [31]. Furthermore, integrating a more exhaustive mutagenesis scheme, such as whole 
gene error-prone PCR [2], may yield libraries consisting of stabilizing framework mutations that 
may compensate for destabilizing loop modifications. Although the number of transformants 
screened in this study (3 × 107) is considerable, the apparent presence of VL-only or VH-only 
domains resulting from yeast homologous recombination may markedly diminish the 
functionality of the library. By increasing the size of the library, we may similarly increase the 
putative number of soluble binders in the library that may be enriched. Thus, a more populous 
library universally improves the likelihood of discovering biophysically superior 4D5 variants. 
  
  
62 
Conclusion 
The findings of this study demonstrate that engineered 4D5 clones isolated from libraries of 
diversified 4D5-TCR chimeras exhibit TCR-like peptide selectivity against the selected antigens 
HLA-A2-Mart1 and HLA-A2-Ny-Eso-1. Importantly, these results suggest that the binding 
domains of TCRs can be transferred to the 4D5 scaffold such that the resulting libraries express 
efficiently in yeast display, in contrast to the TCRs from which the libraries are derived [32]. 
Although synthetic and pre-immune 4D5 libraries may be used to select against pMHC antigens, 
ensuing hits are unlikely to possess TCR-like peptide selectivity, given the myriad 
immunodominant epitopes of HLA-A2 and diverse binding modes that can be accommodated [33]. 
In contrast, constructing libraries by transplanting the binding domains of well-validated, peptide-
selective TCRs likely predisposes library clones toward TCR-like binding modes. Moreover, 
although TCRs are generally refractory to display formats and are thus challenging to engineer, 
selected 4D5 variants, such as Ny.1 and Ma.2, are demonstrably amenable to yeast display 
selection. Consequently, such clones may be further engineered for greater affinity and, with 
suitable methods, for improved solubility. In particular, constructing larger libraries, and using 
technologies such as secretion-and-capture yeast display or high-throughput, single-cell microarrays 
increases the number of evaluable hits and the likelihood that such hits can be solubly expressed, 
respectively. Therefore, such approaches are expected to improve the chances of future efforts 
exploiting the TCR-to-4D5 methodology to attain soluble reagents with TCR-like selectivity for 
pMHC antigens. 
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Figure 3-1. Pairwise sequence alignment of 4D5 and T cell receptor V-regions. (A) 
DMF5 TCR Vα domain (top) aligned to 4D5 VL (bottom). (B) DMF5 TCR Vβ 
domain (top) aligned to 4D5 VH (bottom). 
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Loop Sequence Source TCR WT TCR sequence WT 4D5 sequence 
CDR-L1 - - - - 
CDR-L3 - - - - 
CDR-H1 MRHGAIH TCR DMF5 MRHNAMY FNIKDTYIH 
CDR-H2 WSSAAGTTR TCR DMF5 YSNTAGTTG RIYPTNGYTR 
CDR-H3 PWSFGTEAL TCR DMF5 SLSFGTEAF WGGDGFYAMDY 
 
Loop Sequence Source TCR WT TCR sequence WT 4D5 sequence 
CDR-L1 GRGSQS TCR DMF5 DRGSQS QDVNTA 
CDR-L3 DPGGGKLT TCR DMF5 NFGGGKLI HYTTPPT 
CDR-H1 FNHNAMY TCR DMF5 MRHNAMY FNIKDTYIH 
CDR-H2 YSNAAGATG TCR DMF5 YSNTAGTTG RIYPTNGYTR 
CDR-H3 SLSFGTEAS TCR DMF5 SLSFGTEAF WGGDGFYAMDY 
 
Loop Sequence Source TCR WT TCR sequence WT 4D5 sequence 
CDR-L1 QYAIYDLR TCR 1G4 SAIYNLQ QDVNTAVA 
CDR-L3 RSLLDGTHTP TCR c58/c61 RPLLDGTYIP 
 
HYTTPP 
CDR-H1 VNHGYIH TCR 1G4 MNHEY FNIKDTYIH 
CDR-H2 YPVDAGITD TCR 1G4 YSVGAGITD RIYPTNGYTR 
CDR-H3 SYVGNTGELF TCR 1G4 SYVGNTGELF WGGDGFYAMDY 
Table 3-1. Loop sequences of dominant clones (A) Ma.1h, (B) Ma.2, and (C) Ny.1. 
Amino acids that differ relative to the parental TCR sequence (resulting from error-prone 
PCR) are highlighted in red. Positions that revert to the amino acid identity of wild-type 
Fn3 are highlighted in blue. 
A 
B 
C 
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Figure 3-2. FACS plots demonstrating the selectivity of various engineered 4D5 
variants for cognate pMHC antigen in yeast display. Ny.1 exhibits no apparent binding 
for (A) HLA-A2-Mart1, yet binds positively to (B) HLA-A2-Ny-Eso-1. Ma.1h 
selectively binds to (C) HLA-A2-Mart1 over (D) HLA-A2-Ny-Eso-1. Ma.2 binds 
appreciably more to (E) HLA-A2-Mart1 than to (F) HLA-A2-Ny-Eso-1. 
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 Figure 3-3. Equilibrium affinity titration of (A) HLA-A2-Ny-Eso-1 tetramer against 
yeast displayed Ny.1, and (B) HLA-A2-Mart1 tetramer against displayed Ma.2. 
A 
B 
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Figure 3-4. (A) Gel filtration profile of soluble Ma.2 Fab. The single, prominent 
corresponds to the expected size of the engineered 4D5 Fab. (B) Standards from 
the AKTA manual for comparison. 
 
A 
B 
  
68 
 
 
 
 
 
 
 
  
Figure 3-5. SPR characterization of soluble Ma.2 Fab. Response following injections 
of increasing concentrations of Ma.2 Fab demonstrates dose-dependent binding, 
although clearly apparent only for the two highest concentrations of Ma.2 assayed. 
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